Loading...
•
Oct 02, 2021
Haemonetics Q2 2022 Earnings Report
Haemonetics reported second quarter fiscal 2022 results with revenue increases across all businesses.
Key Takeaways
Haemonetics Corporation reported a 14.5% increase in revenue compared to the second quarter of fiscal 2021. The company's Plasma and Hospital businesses are expected to continue growth in the second half of fiscal 22.
Second quarter fiscal 2022 revenue was $239.9 million, up 14.5% compared with second quarter fiscal 2021.
Earnings per diluted share was $0.29, compared to $0.94 in the same quarter last year.
Adjusted earnings per diluted share was $0.60, compared to $0.62 last year.
Cash flow from operating activities was $42.7 million and free cash flow before restructuring and restructuring related costs was $29.3 million.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company revised its GAAP total revenue growth guidance from 13 – 18% to 13 – 17% and organic revenue growth guidance issued on November 9, 2021.
Positive Outlook
- Total revenue growth is expected to be 13-17%.
- Organic revenue growth is expected to be 7-10%.
- Hospital revenue growth is expected to be 15-20%.
- Hemostasis Management organic revenue growth rate in the mid-twenties.
- Total company GAAP revenue guidance includes $80 - $90 of million revenue related to Vascular Closure.
Challenges Ahead
- Plasma revenue growth is expected to be 10-20%, down from 15-25%.
- Blood Center revenue growth is expected to be -3 to -5%, down from -6 to -8%.
- Adjusted operating margin is expected to be 18-19%, down from 19-20%.
- Adjusted earnings per diluted share is expected to be $2.40 - $2.65, down from $2.60 - $3.00.
- Free cash flow, before restructuring & restructuring related costs is expected to be $115M - $135M, down from $135M - $155M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income